FDA approves CSL Behring's Berinert for use in children under 12
King of Prussia-based pharmaceutical company CSL Behring says the Food and Drug Administration has approved its intravenous treatment, Berinert, for children under 12 to treat hereditary angioedema attacks, a rare genetic condition that causes swelling in various body parts, including hands, feet, face, and airway.
King of Prussia-based pharmaceutical company CSL Behring says the Food and Drug Administration has approved its intravenous treatment, Berinert, for children under 12 to treat hereditary angioedema attacks, a rare genetic condition that causes swelling in various body parts, including hands, feet, face, and airway.
Children have a 50 percent chance of inheriting the disease from a parent. The treatment, approved for adults by the FDA in 2009, is the first approved therapy for pediatric patients, the company said.
CSL Behring, which employs more than 500 at its King of Prussia headquarters, makes products to treat bleeding disorders, such as hemophilia and Von Willebrand disease, and immune-deficiency diseases. The company is a unit of Australia's CSL Ltd.
215-854-2831
@LoydLinda